Published in Ther Clin Risk Manag on June 01, 2007
Switch from selegiline to rasagiline is beneficial in patients with Parkinson's disease. J Neural Transm (Vienna) (2012) 0.83
Editorial. Ther Clin Risk Manag (2007) 0.75
Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy. Parkinsons Dis (2016) 0.75
Rasagiline for sleep disorders in patients with Parkinson's disease: a prospective observational study. Neuropsychiatr Dis Treat (2016) 0.75
Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging (2002) 22.40
Molecular pathways of neurodegeneration in Parkinson's disease. Science (2003) 7.55
Inflammation and neurodegeneration in Parkinson's disease. Parkinsonism Relat Disord (2004) 2.41
A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol (2004) 2.34
Rasagiline: A second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm (2006) 2.09
Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. Proc Natl Acad Sci U S A (2000) 1.97
Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth (2005) 1.97
Early environmental origins of neurodegenerative disease in later life. Environ Health Perspect (2005) 1.80
A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol (2002) 1.80
Vascular parkinsonism--an important cause of parkinsonism in older people. Age Ageing (2005) 1.71
Mitochondria-targeted peptide antioxidants: novel neuroprotective agents. AAPS J (2006) 1.65
A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol (2005) 1.62
Apoptosis in Parkinson's disease: signals for neuronal degradation. Ann Neurol (2003) 1.55
Rasagiline: defining the role of a novel therapy in the treatment of Parkinson's disease. Int J Clin Pract (2006) 1.41
Increased caspase 3 and Bax immunoreactivity accompany nuclear GAPDH translocation and neuronal apoptosis in Parkinson's disease. Exp Neurol (2000) 1.36
Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection. Ann Neurol (1998) 1.22
Blockade of nociceptin/orphanin FQ transmission attenuates symptoms and neurodegeneration associated with Parkinson's disease. J Neurosci (2005) 1.06
Pharmacodynamic aspects of modes of drug administration for optimization of drug therapy. Crit Rev Ther Drug Carrier Syst (1999) 1.00
Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms. Int J Pharm (2004) 0.99
Therapeutic potential of neurotrophic factors in neurodegenerative diseases. BioDrugs (2005) 0.97
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol (2001) 0.96
Neuroprotective therapy in Parkinson's disease and motor complications: a search for a pathogenesis-targeted, disease-modifying strategy. Mov Disord (2005) 0.92
Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep (2005) 0.90
Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients. Mov Disord (2004) 0.89
Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J Neural Transm (Vienna) (2001) 0.89
Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor. Pharmacotherapy (2004) 0.88
Treatment of Parkinson's disease : what's on the horizon? CNS Drugs (2005) 0.88
Effects of N-propargyl-1-(R)aminoindan (rasagiline) in models of motor and cognition disorders. J Neural Transm Suppl (1998) 0.86
Rasagiline improves quality of life in patients with early Parkinson's disease. Mov Disord (2006) 0.85
New pharmacologic horizons in the treatment of Parkinson disease. Neurology (2006) 0.85
Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol (2002) 0.84
Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. J Neurol Sci (2006) 0.82
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays (2004) 0.81
Tolcapone in the management of Parkinson's disease. Expert Opin Pharmacother (2006) 0.80
Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on levodopa absorption in humans. Pharm Res (2003) 0.77
N-methylation of peptides: a new perspective in medicinal chemistry. Acc Chem Res (2008) 2.02
Nerve growth factor-endothelial cell interaction leads to angiogenesis in vitro and in vivo. FASEB J (2002) 1.61
Improving oral bioavailability of peptides by multiple N-methylation: somatostatin analogues. Angew Chem Int Ed Engl (2008) 1.48
In vitro and in vivo reversal of MDR1-mediated multidrug resistance by KT-5720: implications on hematological malignancies. Leuk Res (2006) 1.42
It's time to choose the study design!: net benefit analysis of alternative study designs to acquire information for evaluation of health technologies. Pharmacoeconomics (2007) 1.38
Expandable gastroretentive dosage forms. J Control Release (2003) 1.27
Interactions between the cells of the immune and nervous system: neurotrophins as neuroprotection mediators in CNS injury. Prog Brain Res (2004) 1.22
Continuity and adherence to long-term drug treatment by geriatric patients after hospital discharge: a prospective cohort study. Drugs Aging (2008) 1.12
The effect of multiple N-methylation on intestinal permeability of cyclic hexapeptides. Mol Pharm (2011) 1.10
Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway. Cell Signal (2011) 1.10
Rationalizing the selection of oral lipid based drug delivery systems by an in vitro dynamic lipolysis model for improved oral bioavailability of poorly water soluble drugs. J Control Release (2008) 1.06
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma. Clin Cancer Res (2003) 1.05
Nerve growth factor-induced migration of endothelial cells. J Pharmacol Exp Ther (2005) 1.04
Neuroprotection by cord blood neural progenitors involves antioxidants, neurotrophic and angiogenic factors. Exp Neurol (2008) 1.03
Neuroprotection by NGF in the PC12 in vitro OGD model: involvement of mitogen-activated protein kinases and gene expression. Ann N Y Acad Sci (2005) 1.03
Regulatory effect of nerve growth factor in alpha9beta1 integrin-dependent progression of glioblastoma. Neuro Oncol (2008) 1.02
Integrin alpha9 beta1 is a receptor for nerve growth factor and other neurotrophins. J Cell Sci (2008) 1.02
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma. Breast Cancer Res Treat (2004) 1.01
Intestinal permeability of cyclic peptides: common key backbone motifs identified. J Am Chem Soc (2012) 1.00
The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia. Atherosclerosis (2005) 1.00
Backbone cyclic peptidomimetic melanocortin-4 receptor agonist as a novel orally administrated drug lead for treating obesity. J Med Chem (2008) 0.98
Neuroprotection by human umbilical cord blood-derived progenitors in ischemic brain injuries. Arch Ital Biol (2011) 0.95
The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci (2010) 0.95
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma. Clin Exp Metastasis (2003) 0.94
Tissue regeneration potential in human umbilical cord blood. Best Pract Res Clin Haematol (2010) 0.94
The role of the lymphatic system in subcutaneous absorption of macromolecules in the rat model. Eur J Pharm Biopharm (2007) 0.92
Determination of metformin transfer across the human placenta using a dually perfused ex vivo placental cotyledon model. Eur J Obstet Gynecol Reprod Biol (2007) 0.92
Co-electrospun blends of PLGA, gelatin, and elastin as potential nonthrombogenic scaffolds for vascular tissue engineering. Biomacromolecules (2010) 0.92
Furosemide pharmacokinetics and pharmacodynamics following gastroretentive dosage form administration to healthy volunteers. J Clin Pharmacol (2003) 0.91
The oral absorption of phospholipid prodrugs: in vivo and in vitro mechanistic investigation of trafficking of a lecithin-valproic acid conjugate following oral administration. J Control Release (2007) 0.91
Neuroprotective effects of carnosine and homocarnosine on pheochromocytoma PC12 cells exposed to ischemia. J Neurosci Res (2002) 0.90
The effect of different lipid based formulations on the oral absorption of lipophilic drugs: the ability of in vitro lipolysis and consecutive ex vivo intestinal permeability data to predict in vivo bioavailability in rats. Eur J Pharm Biopharm (2007) 0.90
Multiple N-methylation by a designed approach enhances receptor selectivity. J Med Chem (2007) 0.89
The effect of general anesthesia on the intestinal lymphatic transport of lipophilic drugs: comparison between anesthetized and freely moving conscious rat models. Eur J Pharm Sci (2007) 0.89
Structure-activity relationship and metabolic stability studies of backbone cyclization and N-methylation of melanocortin peptides. Biopolymers (2008) 0.89
Effect of VP12 and viperistatin on inhibition of collagen-receptor-dependent melanoma metastasis. Cancer Biol Ther (2009) 0.89
Effect of a high-fat meal on absorption and disposition of lipophilic compounds: the importance of degree of association with triglyceride-rich lipoproteins. Eur J Pharm Sci (2007) 0.89
Uptake of lipophilic drugs by plasma derived isolated chylomicrons: linear correlation with intestinal lymphatic bioavailability. Eur J Pharm Sci (2005) 0.89
Nerve growth factor-induced protection of brain capillary endothelial cells exposed to oxygen-glucose deprivation involves attenuation of Erk phosphorylation. J Mol Neurosci (2009) 0.89
Fibronectin-mediated upregulation of α5β1 integrin and cell adhesion during differentiation of mouse embryonic stem cells. Cell Adh Migr (2011) 0.89
Pharmacokinetic-pharmacodynamic analysis of the glucose-lowering effect of metformin in diabetic rats reveals first-pass pharmacodynamic effect. Drug Metab Dispos (2002) 0.89
Roles of Ras-Erk in apoptosis of PC12 cells induced by trophic factor withdrawal or oxidative stress. J Mol Neurosci (2005) 0.89
Evaluation of a chylomicron flow blocking approach to investigate the intestinal lymphatic transport of lipophilic drugs. Eur J Pharm Sci (2005) 0.88
Neural stem cells: therapeutic potential for neurodegenerative diseases. Br Med Bull (2012) 0.87
Carrier-mediated transport of metformin across the human placenta determined by using the ex vivo perfusion of the placental cotyledon model. Prenat Diagn (2008) 0.87
Neuronal conditioning medium and nerve growth factor induce neuronal differentiation of collagen-adherent progenitors derived from human umbilical cord blood. J Mol Neurosci (2007) 0.86
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions. Gynecol Oncol (2003) 0.86
Apoptotic characteristics of cell death and the neuroprotective effect of homocarnosine on pheochromocytoma PC12 cells exposed to ischemia. J Neurosci Res (2004) 0.86
Bone as an effect compartment : models for uptake and release of drugs. Clin Pharmacokinet (2003) 0.86
Effect of structural and conformation modifications, including backbone cyclization, of hydrophilic hexapeptides on their intestinal permeability and enzymatic stability. J Med Chem (2007) 0.85
Improvement of drug-like properties of peptides: the somatostatin paradigm. Expert Opin Drug Discov (2010) 0.85
Developing potent backbone cyclic peptides bearing the shared epitope sequence as rheumatoid arthritis drug-leads. Bioorg Med Chem Lett (2011) 0.84
Cetuximab-labeled liposomes containing near-infrared probe for in vivo imaging. Nanomedicine (2011) 0.84
A signal transduction pharmacodynamic model of the kinetics of the parasympathomimetic activity of low-dose scopolamine and atropine in rats. J Pharm Sci (2002) 0.84
Neuroprotective and neurotoxic effects of monoamine oxidase-B inhibitors and derived metabolites under ischemia in PC12 cells. Eur J Pharmacol (2002) 0.84
High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. Anesth Analg (2010) 0.83
Nerve growth factor reduces myocardial ischemia/reperfusion injury in rat hearts. J Basic Clin Physiol Pharmacol (2013) 0.83
The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma. Hum Pathol (2006) 0.83
Nerve growth factor pretreatment attenuates oxygen and glucose deprivation-induced c-Jun amino-terminal kinase 1 and stress-activated kinases p38alpha and p38beta activation and confers neuroprotection in the pheochromocytoma PC12 Model. J Mol Neurosci (2004) 0.83
Angiostatic effects of K252a, a Trk inhibitor, in murine brain capillary endothelial cells. Mol Cell Biochem (2010) 0.83
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome. Am J Clin Pathol (2004) 0.82
Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions. Int J Clin Pharm (2012) 0.82
Posttranslational control of a cardiac ion channel transgene in vivo: clarithromycin-hMiRP1-Q9E interactions. Hum Gene Ther (2005) 0.82
High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Res (2011) 0.82
Hypoxia enhances differentiation of mouse embryonic stem cells into definitive endoderm and distal lung cells. Stem Cells Dev (2014) 0.82
Pardaxin, an ionophore neurotoxin, induces PC12 cell death: activation of stress kinases and production of reactive oxygen species. J Nat Toxins (2002) 0.82
A novel mechanism for oral controlled release of drugs by continuous degradation of a phospholipid prodrug along the intestine: in-vivo and in-vitro evaluation of an indomethacin-lecithin conjugate. J Control Release (2007) 0.82
Gastroretentive Accordion Pill: Enhancement of riboflavin bioavailability in humans. J Control Release (2006) 0.82
Bio-imaging of colorectal cancer models using near infrared labeled epidermal growth factor. PLoS One (2012) 0.82
Cardiac microvascular endothelial cells express and release nerve growth factor but not fibroblast growth factor-2. In Vitro Cell Dev Biol Anim (2010) 0.82
Novel D-xylose derivatives stimulate muscle glucose uptake by activating AMP-activated protein kinase alpha. J Med Chem (2008) 0.82
The effect of backbone cyclization on PK/PD properties of bioactive peptide-peptoid hybrids: the melanocortin agonist paradigm. Bioorg Med Chem (2009) 0.82
Structural determinants of the selectivity of KTS-disintegrins for the alpha1beta1 integrin. FEBS Lett (2004) 0.82
Importance of interaction between nerve growth factor and α9β1 integrin in glial tumor angiogenesis. Neuro Oncol (2012) 0.81
Novel gastroretentive dosage forms: evaluation of gastroretentivity and its effect on riboflavin absorption in dogs. Pharm Res (2002) 0.81
Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease? Bioessays (2004) 0.81
Pardaxin, a fish toxin peptide interaction with a biomimetic phospholipid/polydiacetylene membrane assay. Peptides (2008) 0.81
Neuroprotective effects of nimodipine and nifedipine in the NGF-differentiated PC12 cells exposed to oxygen-glucose deprivation or trophic withdrawal. Int J Dev Neurosci (2012) 0.81
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma. Lung Cancer (2004) 0.81
VEGF-related protein isolated from Vipera palestinae venom, promotes angiogenesis. Growth Factors (2007) 0.81
Different impacts of intestinal lymphatic transport on the oral bioavailability of structurally similar synthetic lipophilic cannabinoids: dexanabinol and PRS-211,220. Eur J Pharm Sci (2007) 0.81
Quantitative assessment of neuronal differentiation in three-dimensional collagen gels using enhanced green fluorescence protein expressing PC12 pheochromocytoma cells. J Mol Neurosci (2008) 0.80
Peaceful use of disastrous neurotoxicants. Neurotoxicology (2010) 0.80
Tissue factor activity and ECM-related gene expression in human aortic endothelial cells grown on electrospun biohybrid scaffolds. Biomacromolecules (2013) 0.80
Distribution of amphotericin B-arabinogalactan conjugate in mouse tissue and its therapeutic efficacy against murine aspergillosis. Antimicrob Agents Chemother (2004) 0.80
Angioneural crosstalk in scaffolds with oriented microchannels for regenerative spinal cord injury repair. J Mol Neurosci (2012) 0.80
Pharmacokinetic and pharmacodynamic evaluation of intermittent versus continuous alendronate administration in rats. J Pharm Sci (2002) 0.80